tirzepatide trials FDA Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes New research from the SURPASS-EARLY

And, of the dozens of medications deprescribed, 4 patients were taken off GLP-1s and did not gain back weight which is counter to the common knowledge that the fat returns when you terminate these medications

Writing your injection day on your calendar, setting a phone reminder, or linking it to another weekly habit removes guesswork and reduces the urge to take doses early

Calocurb activates the bitter brake, mimicking a natural, evolution response to bitter foods to create a feeling of fullness

84, 85 AT 2 receptor-mediated vasodilator and depressor actions of Ang II appear more easily when AT 1 receptors are blocked by AT 1 receptor antagonists